Abstract
Decitabine is widely accepted as the treatment options for elderly acute myeloid leukemia (AML) patients. However, the efficacy has yet been assessed in Asian population. We retrospectively analyzed the outcomes of 80 Korean elderly AML patients who were treated with decitabine. The median age was 74 years (range, 64 to 86 years) and 6 (7.5%), 48 (60.0%), and 25 (31.3%) patients were categorized to favorable, intermediate, and poor risk group, respectively. The median OS was 10.2 months (95% CI 5.0-15.4). Given that decitabine treatment demonstrated improved clinical outcomes, it could be considered as one of the first-line treatment for Korean elderly AML patients.
References
Sep 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B LöwenbergS Suciu
Jan 16, 2002·Current Opinion in Oncology·Mikkael A Sekeres, Richard M Stone
Sep 28, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Anoop Kumar EnjetiChristina Rudduck Sivaswaren
Mar 15, 2006·Cancer·Hagop KantarjianHussain Saba
Nov 15, 2008·Blood·Gunnar JuliussonMartin Höglund
Feb 24, 2009·The Lancet Oncology·Pierre FenauxUNKNOWN International Vidaza High-Risk MDS Survival Study Group
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amanda F CashenJohn F DiPersio
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FenauxLewis R Silverman
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael LübbertPierre W Wijermans
Oct 4, 2011·Cancer Genetics·Chi-Chiu SoLi-Chong Chan
Mar 3, 2012·Blood·Gunnar JuliussonUNKNOWN Swedish Acute Leukemia Registry Group
Jun 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagop M KantarjianChristopher Arthur
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Sep 14, 2013·Journal of the National Comprehensive Cancer Network : JNCCN·Margaret R O'DonnellUNKNOWN National Comprehensive Cancer Network
Jul 6, 2014·International Journal of Hematology·Soo-Jeong KimUNKNOWN Korean Society of Hematology AML/MDS Working Party